시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 관절통 시장 보고서(2025년)
Arthralgia Global Market Report 2025
상품코드 : 1720715
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,242,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,023,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,803,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

관절통 시장 규모는 향후 몇 년간 강력한 성장이 전망될 예정입니다. 예측 기간의 성장은 관절통에 대한 인식 증가, 노인 인구 증가, 의료 인프라 확대, 최소 침습적 치료에 대한 수요 증가, 스포츠 부상 유병률 증가에 의해 주도될 것으로 예상됩니다.

류마티스 관절염 증가는 향후 몇 년 동안 관절통 시장의 성장을 가속할 것으로 예측됩니다. 흡연이나 오염 등의 환경 요인 등의 요인에 기인하고 있습니다 류마티스 관절염는 만성적인 관절의 염증을 일으켜, 통증, 경직, 진행성의 손상을 초래하는 것으로, 관절통의 일인이 되고 있습니다. 예를 들면, 2024년 2월, 호주에 거점으로 있는 Arthritis Australia는 2040년까지 호주에서 관절염 환자 수가 2025년 411만명에서 539만명으로 증가하고, 류마티스 관절염 환자 수는 74만 8,721명에 이를 것으로 예측했습니다.

관절통 시장의 각 회사는 장기적인 통증 완화와 관절 기능 개선을 가져오는 RMAT 지정 유전자 치료 등의 혁신적인 치료법의 개발에 주력하고 있습니다. RMAT 지정 유전자 치료제는 심각하거나 생명을 위협하는 질환에 대한 유전자 치료제의 개발 및 심사를 가속화하는 FDA의 재생 의학 첨단 치료(RMAT) 지정을 받은 치료제를 말합니다. 2024년 3월, 미국에 본사를 둔 제약 회사인 파시라 바이오사이언스는 미국 식품의약국(FDA)으로부터 자사 제품 PCRX-201(에네킨라진 인자데노벡)에 대한 RMAT 지정을 받았습니다. PCRX-201은 인터루킨-1 수용체 길항제(IL-1Ra)를 생성하는 헬퍼 의존성 아데노바이러스(HDAd)를 사용하여 무릎 골관절염을 치료하도록 설계된 혁신적인 관절 내 유전자 치료 후보물질입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Arthralgia refers to pain in one or more joints, usually without inflammation, and can stem from various causes, including infections, autoimmune diseases, or injuries. It is a symptom rather than a standalone condition, often indicating an underlying health issue affecting the joints.

The primary causes of arthralgia include osteoarthritis, rheumatoid arthritis, gout, psoriatic arthritis, lupus, injuries, infections, and other contributing factors. Osteoarthritis is a degenerative joint disease that develops when the protective cartilage cushioning the ends of bones gradually wears down. A range of treatment options is available, including medications, therapies, surgical interventions, and lifestyle or home remedies. These treatments can be administered through different methods, such as oral, injectable, topical, and transdermal routes. They are distributed via hospital pharmacies, retail pharmacies, and online pharmacies and are used across various settings, including hospitals, clinics, home care environments, and rehabilitation centers.

The arthralgia market research report is one of a series of new reports from The Business Research Company that provides arthralgia market statistics, including the arthralgia industry global market size, regional shares, competitors with the arthralgia market share, detailed arthralgia market segments, market trends, and opportunities, and any further data you may need to thrive in the arthralgia industry. This arthralgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The arthralgia market size has grown strongly in recent years. It will grow from $5.20 billion in 2024 to $5.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising prevalence of autoimmune diseases, the increasing incidence of various associated risk factors, the growing rates of obesity, the higher prevalence of arthralgia, and the increasing occurrence of joint disorders.

The arthralgia market size is expected to see strong growth in the next few years. It will grow to $7.73 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period is expected to be driven by increasing awareness of arthralgia, a growing geriatric population, expanding healthcare infrastructure, rising demand for minimally invasive treatments, and the increasing prevalence of sports injuries. Key trends during this period include the integration of digital health solutions, the development of novel therapies and cell therapies, advancements in medical technology, and increased investment in research and development.

The increasing incidence of rheumatoid arthritis is expected to drive the growth of the arthralgia market in the coming years. Rheumatoid arthritis is a chronic autoimmune condition that primarily impacts the joints, causing inflammation, pain, and potential joint damage. The rise in rheumatoid arthritis cases can be attributed to factors such as an aging population, genetic predisposition, lifestyle changes, and environmental factors such as smoking and pollution. Rheumatoid arthritis contributes to arthralgia by causing chronic joint inflammation, leading to pain, stiffness, and progressive damage. For example, in February 2024, Arthritis Australia, a non-profit organization based in Australia, projected that by 2040, arthritis cases in Australia would increase to 5.39 million from 4.11 million in 2025, with rheumatoid arthritis cases reaching 748,721. Consequently, the growing number of rheumatoid arthritis cases is fueling the expansion of the arthralgia market.

Companies in the arthralgia market are focusing on developing innovative treatments, such as RMAT-designated gene therapies, to provide long-term pain relief and improved joint function. RMAT-designated gene therapy refers to a treatment that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which accelerates the development and review of gene therapies for serious or life-threatening conditions. In March 2024, Pacira BioSciences Inc., a US-based pharmaceutical company, received RMAT designation for its product PCRX-201 (enekinragene inzadenovec) from the U.S. Food and Drug Administration (FDA). PCRX-201 is an innovative intra-articular gene therapy candidate designed to treat knee osteoarthritis using a helper-dependent adenovirus (HDAd) to produce interleukin-1 receptor antagonists (IL-1Ra). Pacira emphasized the promising preliminary clinical results, suggesting that PCRX-201 could become a potential disease-modifying treatment for osteoarthritis.

In November 2023, Nevro Corp., a US-based medical device company, acquired Vyrsa Technologies for $75 million. This acquisition allows Nevro to expand its chronic pain treatment portfolio by incorporating Vyrsa Technologies' minimally invasive SI joint fusion devices. By enhancing its market presence, Nevro aims to provide advanced solutions for long-term pain relief to patients suffering from chronic sacroiliac (SI) joint pain. Vyrsa Technologies, a US-based company, specializes in treating arthralgia, specifically addressing chronic SI joint pain.

Major players in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation, and Vitazan Herbs and Vitamins Inc.

North America was the largest region in the arthralgia market in 2024. The regions covered in arthralgia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the arthralgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The arthralgia market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, physical rehabilitation programs, and supportive services. The market value includes the value of related goods sold by the service provider or included within the service offering. The arthralgia market also includes sales of musculoskeletal diagnostic tools, biologic drugs, anti-inflammatory drugs, and regenerative therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Arthralgia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on arthralgia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for arthralgia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The arthralgia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Arthralgia Market Characteristics

3. Arthralgia Market Trends And Strategies

4. Arthralgia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Arthralgia Growth Analysis And Strategic Analysis Framework

6. Arthralgia Market Segmentation

7. Arthralgia Market Regional And Country Analysis

8. Asia-Pacific Arthralgia Market

9. China Arthralgia Market

10. India Arthralgia Market

11. Japan Arthralgia Market

12. Australia Arthralgia Market

13. Indonesia Arthralgia Market

14. South Korea Arthralgia Market

15. Western Europe Arthralgia Market

16. UK Arthralgia Market

17. Germany Arthralgia Market

18. France Arthralgia Market

19. Italy Arthralgia Market

20. Spain Arthralgia Market

21. Eastern Europe Arthralgia Market

22. Russia Arthralgia Market

23. North America Arthralgia Market

24. USA Arthralgia Market

25. Canada Arthralgia Market

26. South America Arthralgia Market

27. Brazil Arthralgia Market

28. Middle East Arthralgia Market

29. Africa Arthralgia Market

30. Arthralgia Market Competitive Landscape And Company Profiles

31. Arthralgia Market Other Major And Innovative Companies

32. Global Arthralgia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Arthralgia Market

34. Recent Developments In The Arthralgia Market

35. Arthralgia Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기